David Dodd, Chairman and CEO at Aeterna Zentaris stated, "We are very excited regarding this agreement for zoptarelin doxorubicin with Sinopharm, the largest pharmaceutical company in China, which is one of the major domestic markets in the world for pharmaceutical products. Women with advanced endometrial cancer are in need of additional treatments, and zoptarelin doxorubicin might prove to be a significant treatment option for them. This agreement is also consistent with our strategy of leveraging our pipeline to secure future revenues with strategic development and commercial licensees for specific regions of the world."
News 
Market Data 
Discover 
AI
